Found: 7
Select item for more details and to access through your institution.
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
- Published in:
- Nephrology Dialysis Transplantation, 2022, v. 37, n. 7, p. 1261, doi. 10.1093/ndt/gfab336
- By:
- Publication type:
- Article
Study Design and Rationale of a Dose-Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy.
- Published in:
- Clinical Cardiology, 2013, v. 36, n. 7, p. 367, doi. 10.1002/clc.22125
- By:
- Publication type:
- Article
Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy.
- Published in:
- Diabetes Care, 2015, v. 38, n. 3, p. 431, doi. 10.2337/dc14-0890
- By:
- Publication type:
- Article
53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-53-OR
- By:
- Publication type:
- Article
1023-P: Do Baseline Characteristics Impact Efficacy of Efpeglenatide QW in Uncontrolled Type 2 Diabetes?
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1023-P
- By:
- Publication type:
- Article
1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1014-P
- By:
- Publication type:
- Article
1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1001-P
- By:
- Publication type:
- Article